Source-grounded facts extracted from Immunocore Holdings plc's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Immunocore Holdings plc shareholders approved Authorization to make political donations/incur political expenditure at the 2026-05-27 meeting.
“Resolution 10 : To authorize the Company to make political donations/incur political expenditure. The votes were cast as follows: For Against Abstain 38,213,340 82,113 8,387”
Immunocore Holdings plc shareholders approved Approval of directors' remuneration report for 2025 (excluding policy) at the 2026-05-27 meeting.
“Resolution 9 : To approve the directors’ remuneration report for the year ended December 31, 2025, which is set forth as Annex A to the Proxy Statement and on pages 26 to 56 of the 2025 U.K. Annual Report (excluding the directors’ remuneration policy set out on pages A-5 to A-15 of Annex A to the Proxy Statement). The votes were cast as follows: For Against Abstain 29,504,692 8,713,573 85,575”
Immunocore Holdings plc shareholders approved Receive and adopt U.K. statutory annual accounts and reports for 2025 at the 2026-05-27 meeting.
“Resolution 8 : To receive and adopt the U.K. statutory annual accounts and reports for the year ended December 31, 2025 (the “2025 U.K. Annual Report”). The votes were cast as follows: For Against Abstain 38,287,987 944 14,909”
Immunocore Holdings plc shareholders approved Authorization to audit committee to determine U.K. statutory auditors’ remuneration for 2026 at the 2026-05-27 meeting.
“Resolution 7 : To authorize the audit committee to determine the U.K. statutory auditors’ remuneration for the year ending December 31, 2026. The votes were cast as follows: For Against Abstain 38,293,269 2,481 8,090”
Immunocore Holdings plc shareholders approved Re-appointment of Deloitte LLP as U.K. statutory auditors at the 2026-05-27 meeting.
“Resolution 6 : To re-appoint Deloitte LLP, a limited liability partnership organized under the laws of England, as the Company’s U.K. statutory auditors, to hold office until the conclusion of the next annual general meeting of shareholders. The votes were cast as follows: For Against Abstain 38,294,523 966 8,351”
Immunocore Holdings plc shareholders approved Ratification of Deloitte LLP as U.S. independent registered public accounting firm for 2026 at the 2026-05-27 meeting.
“Resolution 5: To ratify the appointment of Deloitte LLP, a limited liability partnership organized under the laws of England, as the Company’s U.S. independent registered public accounting firm for the year ending December 31, 2026. The votes were cast as follows: For Against Abstain 38,294,666 984 8,190”
Immunocore Holdings plc shareholders approved Advisory vote on compensation of named executive officers at the 2026-05-27 meeting.
“Resolution 4: To approve, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in the Proxy Statement. The votes were cast as follows: For Against Abstain 29,682,169 8,600,029 21,642”
Immunocore Holdings plc shareholders approved Re-appointment of Kristine Peterson as director at the 2026-05-27 meeting.
“Resolution 3 : To re-appoint as a director of the Company Kristine Peterson. The votes were cast as follows: For Against Abstain 29,537,800 8,744,383 21,657”
Immunocore Holdings plc shareholders approved Re-appointment of William Pao as director at the 2026-05-27 meeting.
“Resolution 2 : To re-appoint as a director of the Company William Pao, M.D., Ph.D. The votes were cast as follows: For Against Abstain 38,040,755 254,852 8,233”
Immunocore Holdings plc shareholders approved Re-appointment of Siddharth Kaul as director at the 2026-05-27 meeting.
“Resolution 1 : To re-appoint as a director of the Company Siddharth Kaul. The votes were cast as follows: For Against Abstain 38,033,664 261,819 8,357”
Immunocore Holdings plc reported the first quarter ended March 31, 2026 results: revenue $106.7 million, net income $13.0 million, EPS $0.25.
“2 ef20072537_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Immunocore reports first quarter financial results and provides a business update KIMMTRAK ® (tebentafusp-tebn) Q1 net sales of $106.7 million, growing by 14% year-over-year Oral presentation at AACR: KIMMTRAK doubles likelihood of being alive at five years for patients with HLA-A*02:01 positive metastatic uveal”
William Pao was appointed as Director at Immunocore Holdings plc.
“the Board appointed William Pao, M.D., Ph.D. to serve as a Class II director of the Company, effective February 25, 2025.”
Travis Coy resigned as Director at Immunocore Holdings plc.
“In connection with his entry into the Employment Agreement, Mr. Coy resigned from the Company’s board of directors (the “Board”), effective as of the Effective Date.”
Travis Coy was appointed as Executive Vice President, Chief Financial Officer and Head of Corporate Development at Immunocore Holdings plc.
“On December 31, 2024, Immunocore LLC, an indirect, wholly owned subsidiary of Immunocore Holdings plc (“Parent” and, together with Immunocore LLC, the “Company”), entered into an employment agreement (the “Employment Agreement”) with Travis Coy, pursuant to which Mr. Coy will serve as the Company’s Executive Vice President, Chief Financial Officer and Head of Corporate Development as well as the Company’s principal financial officer, effective as of January 1, 2025 (the “Effective Date”).”
Brian Di Donato resigned as Chief Financial Officer at Immunocore Holdings plc.
“Mr. Brian Di Donato notified Immunocore Holdings plc (the “Company”) of his decision to resign as Executive Vice President, Chief Financial Officer and Head of Strategy and principal financial officer of the Company, effective December 31, 2024, to pursue another opportunity.”
Ranjeev Krishana was appointed as Class I director at Immunocore Holdings plc.
“the Board appointed Mr. Ranjeev Krishana to serve as a Class I director of the Company, effective May 28, 2024.”
Immunocore Holdings plc reported the first quarter ended March 31, 2024 results: revenue Total net product revenue ... was $70.3 million in the first quarter of 2024, net income Net loss for the first quarter of 2024 was $24.4 million, EPS The first quarter basic and diluted loss per share was $0.49.
“On May 8, 2024, Immunocore Holdings plc (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2024, as well as other recent corporate updates.”
Immunocore Holdings plc incurred convertible notes of $402.5 million aggregate principal amount with U.S. Bank Trust Company, National Association at 2.50% per year maturing February 1, 2030.
“On February 2, 2024, Immunocore Holdings plc (the “Company”) completed its previously announced private offering (the “Offering”) of $402.5 million aggregate principal amount of 2.50% Convertible Senior Notes due 2030 (the “Notes”), including the exercise in full of the initial purchasers’ option to purchase up to an additional $52.5 million principal amount of Notes.”
Immunocore Holdings plc entered into Indenture with U.S. Bank Trust Company, National Association valued at $402.5 million aggregate principal amount (effective 2024-02-02).
“The Notes were issued pursuant to an indenture, dated February 2, 2024 (the “Indenture”), between the Company and U.S. Bank Trust Company, National Association, as trustee.”
Immunocore Holdings plc reported the fourth quarter of 2023 and the full year 2023 results: revenue approximately $66 million.
“Immunocore Holdings plc (the “Company”) expects to report preliminary unaudited net product revenue (“net sales”) arising from the sales of KIMMTRAK (tebentafusp) of approximately $66 million for the fourth quarter of 2023 and approximately $235 million for the full year 2023”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.